Latest stories on AZN
AstraZeneca's drug pipeine is splitting opinion among City analysts
Yahoo Top53 · neutralgeneral
Health Care Roundup: Market Talk
WSJ Markets50 · neutralgeneral
Health Care Up Amid Deal Activity — Health Care Roundup
Morningstar63 · neutralproduct/pr
AstraZeneca PLC (AZN) Q2 2026 Earnings Call Transcript
Seeking Alpha50 · neutralearnings
AstraZeneca: Q2 2026 Results Were All Right, But Farxiga Poses Risks
Seeking Alpha56 · neutralearnings
AstraZeneca's Rare Disease Setback Is A 'Clear Positive' For Omeros, Says This Analyst – A Look At Some Key Highlights
Stocktwits News58 · neutralanalyst
Omeros gains as AstraZeneca's Ultomiris fails in rare blood disorder
Seeking Alpha63 · neutralproduct/pr
Astrazeneca Q2 Earnings Call Highlights
Yahoo Top63 · neutralearnings
AstraZeneca Posts Sales Growth on Oncology Strength
Morningstar59 · neutralearnings
AstraZeneca Q2 2026 earnings beat on cancer drug sales - qz.com
Quartz68 · bullishearnings
AstraZeneca Q2 2026 earnings beat on cancer drug sales - qz.com
Quartz68 · bullishearnings
AstraZeneca Q2 2026 earnings beat on cancer drug sales
Yahoo Top68 · bullishearnings
AstraZeneca Sees 2030 Goal on Track as Cancer Drugs Drive Growth — Update
Morningstar63 · neutralproduct/pr
Earnings live: AstraZeneca stock rises to kick off a busy earnings week
Yahoo Finance63 · neutralearnings
AstraZeneca Delivers 6% H1 Revenue Growth and Expands Pipeline with Major Regulatory Wins
MarketChameleon73 · bullishearnings
AstraZeneca PLC 2026 Q2 - Results - Earnings Call Presentation
Seeking Alpha50 · neutralearnings
AstraZeneca results: H1 and Q2 2026 | AZN Stock News
StockTitan50 · neutralearnings
AstraZeneca PLC declares $1.06 interim dividend
Seeking Alpha50 · neutralgeneral
AstraZeneca Q2 profit beats estimates as cancer drug sales drive growth
Seeking Alpha68 · bullishearnings
Why is AstraZeneca stock climbing today?
Investing.com Markets50 · neutralgeneral
Earnings Snapshot: AstraZeneca reports Q2 earnings beat, raises interim dividend, and reaffirms FY26 guidance
Seeking Alpha68 · bullishearnings
AstraZeneca Q2 Non-GAAP EPS tops expectations by $1.36; reconfirms full-year outlook
Seeking Alpha68 · bullishearnings
AstraZeneca Posts Sales Growth on Oncology Strength
WSJ Business63 · neutralearnings
AstraZeneca CFO: Very confident we will hit $80 billion revenue target
CNBC67 · bullishearnings